Adaptimmune Therapeutics PLC – (ADAP) Shares Down 5.5%
Adaptimmune Therapeutics PLC – (NASDAQ:ADAP) traded down 5.5% during mid-day trading on Wednesday . The company traded as low as $6.75 and last traded at $6.76, with a volume of 101,854 shares trading hands. The stock had previously closed at $7.15.
Separately, Zacks Investment Research lowered Adaptimmune Therapeutics PLC – from a “hold” rating to a “sell” rating in a research report on Thursday, August 11th. One analyst has rated the stock with a sell rating and five have assigned a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus target price of $15.94.
The firm has a 50-day moving average of $7.66 and a 200-day moving average of $8.61. The company’s market cap is $474.26 million.
Adaptimmune Therapeutics PLC – (NASDAQ:ADAP) last issued its quarterly earnings results on Monday, August 8th. The company reported ($0.05) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.21) by $0.16. On average, equities research analysts forecast that Adaptimmune Therapeutics PLC – will post ($1.16) earnings per share for the current fiscal year.
An institutional investor recently raised its position in Adaptimmune Therapeutics PLC – stock. Jennison Associates LLC raised its position in shares of Adaptimmune Therapeutics PLC – (NASDAQ:ADAP) by 0.3% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 486,948 shares of the company’s stock after buying an additional 1,547 shares during the period. Jennison Associates LLC owned 0.69% of Adaptimmune Therapeutics PLC – worth $5,873,000 as of its most recent SEC filing.
Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company. The Company is focused on cancer immunotherapy products based on its T-cell receptor (TCR) platform. The Company has developed a platform that enables it to identify cancer targets in the form of peptides, which are short sequences of amino acids, find and genetically engineer TCRs, and produce TCR therapeutic candidates for administration to patients.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.